Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activation

The Canadian Cancer Trials Group is very pleased to announce activation of the Group's second pediatric trial.

Canadian Cancer Trials Group IND.212 -- A Pilot Study of Imetelstat Given Intravenously on Day 1 and 8 of a 21 Day Schedule alone and With Standard 13-cis-retinoic acid in Children with Recurrent and/or Refractory Neuroblastoma -- was centrally activated July 30, 2013.

The primary objectives of the trial are to:
  1. Confirm the feasibility of administering imetelstat given at the recommended pediatric dose as determined in the Children's Oncology Group Study ADVL1112 (a phase I study of imetelstat, a telomerase inhibitor, in children with recurrent or refractory solid tumours and lymphoma), alone and in combination with 13-cis-retinoic acid;
  2. Assess the impact of imetelstat on hematopoietic stem cells and neuroblastoma tumour initiating cells; and,
  3. Evaluate:
    • The correlation of tumour and plasma C-circles.
    • The role of plasma C-circles as a tumour biomarker for alternative lengthening of telomeres (ALT).
    • Changes in plasma C-circles induced by treatment with imetelstat.